Abstract
Head and cell neck squamous carcinomas are a heterogeneous group of neoplasms evolved through multistep carcinogenesis, which is commonly attributed to the abuse of tobacco and alcohol. The epidemiological and molecular evidences from recent decades show the human papillomavirus (HPV) to be causative in a subset of HNSCC. Anatomically, HPV exhibits a predilection for the oral cavity and oropharyngeal and laryngeal regions of the head and neck. HPV-positive and HPV-negative tumors differ in many facets that include histology, differentiation, risk factors, and prognosis. At present, no guidelines are available to choose an appropriate biomarker for the clinical assessment of HPV in HNSCC malignancies. Currently, p16 immunohistochemistry is used as a potential surrogate marker, but its use as a predictive marker is still questionable. Taking the present scenario into consideration, we present in this chapter a list of biomolecules that have higher possibility for use as biomarkers. A randomized clinical trial is required for validation of each biomolecule before designating it as a biomarker that can be subsumed for routine analysis.
Abbreviations
- APC:
-
Adenomatous Polyposis Coli
- ATP:
-
Adenosine Triphosphate
- BER:
-
Base Excision Repair
- CDC:
-
Centers for Disease Control and Prevention
- CH1:
-
Cysteine/Histidine-Rich 1
- CI:
-
Confidence Interval
- DNA:
-
Deoxyribonucleic Acid
- EGFR:
-
Epidermal Growth Factor Receptor
- FDA:
-
Food and Drug Administration
- HLA:
-
Human Leukocyte Antigen
- HNSCC:
-
Head and Neck Squamous Cell Carcinoma
- HPV:
-
Human Papillomavirus
- hTERT:
-
Human Telomerase Reverse Transcriptase
- ISH:
-
In Situ Hybridization
- KRT14:
-
Human Keratin 14
- LCR:
-
Long Control Region
- MCM7:
-
Minimicrosome Protein 7
- MDM2:
-
Mouse Double Minute 2 Homolog
- MHC:
-
Major Histocompatibility Complex
- mMU:
-
Milli-Merk Units
- MPG:
-
Multiplex Human Papillomavirus Genotyping
- OPSCC:
-
Oropharyngeal Squamous Cell Carcinoma
- OR:
-
Odds Ratio
- OSCC:
-
Oral Squamous Cell Carcinoma
- PDCD4:
-
Programmed Cell Death Protein 4
- PSCC:
-
Pharyngeal Squamous Cell Carcinoma
- Rb:
-
Retinoblastoma
- RNA:
-
Ribonucleic Acid
- RTOG:
-
Radiation Therapy Oncology Group
- RT-qPCR:
-
Reverse Transcription Quantitative Polymerase Chain Reaction
- SSB:
-
Single-Strand Break
- TGF:
-
Transforming Growth Factor
- TGFBR3:
-
TGF Beta-Receptor 3
- TIL:
-
Tumor-Infiltrating Lymphocytes
- VLP:
-
Viruslike Particles
- XRCC1:
-
X-ray Repair Cross-Complementing Protein 1
References
Abeloff MD, Armitage J, Niederhuber JE, Kastan MB, et al. Abeloff’s clinical oncology. 4th ed. Philadelphia: Elsevier; 2009.
Agoston ES, Robinson SJ, Mehra KK, et al. Polymerase chain reaction detection of HPV in squamous carcinoma of the oropharynx. Am J Clin Pathol. 2010;134:36–41.
Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35.
Ang MK, Patel MR, Yin XY, et al. High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2011;17:6542–52.
Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
Blow JJ. Preventing re-replication of DNA in a single cell cycle: evidence for a replication licensing factor. J Cell Biol. 1993;122:993–1002.
Bussu F, Sali M, Gallus R, et al. HPV infection in squamous cell carcinomas arising from different mucosal sites of the head and neck region. Is p16 immunohistochemistry a reliable surrogate marker? Br J Cancer. 2013;108:1157–62.
Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene. 2008;27:5869–85.
Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus-related (HPV-R) and unrelated (HPV-U) head and neck squamous cell carcinomas (HNSCC) in the United States (US). J Clin Oncol. 2007;25:6001.
Chen X, Sturgis EM, Lei D, et al. Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. Cancer Res. 2010;70:7199–208.
D’Souza G, Sugar E, Ruby W, et al. Analysis of the effect of DNA purification on detection of human papillomavirus in oral rinse samples by PCR. J Clin Microbiol. 2005;43:5526–35.
Dayyani F, Etzel CJ, Liu M, et al. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010;2:15.
de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology. 2004;324:17–27.
Ernoux-Neufcoeur P, Arafa M, Decaestecker C, et al. Combined analysis of HPV DNA, p16, p21 and p53 to predict prognosis in patients with stage IV hypopharyngeal carcinoma. J Cancer Res Clin Oncol. 2011;137:173–81.
Fountzilas G, Kalogera-Fountzila A, Lambaki S, et al. MMP9 but not EGFR, MET, ERCC1, P16, and P-53 is associated with response to concomitant radiotherapy, cetuximab, and weekly cisplatin in patients with locally advanced head and neck cancer. J Oncol. 2009;2009:305908.
Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein – thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res. 1999;59:1–7.
Furniss CS, McClean MD, Smith JF, et al. Human papillomavirus 16 and head and neck squamous cell carcinoma. Int J Cancer. 2007;120:2386–92.
Gao G, Chernock RD, Gay HA, et al. A novel RT-PCR method for quantification of human papillomavirus transcripts in archived tissues and its application in oropharyngeal cancer prognosis. Int J Cancer. 2013;132:882–90.
Gillison ML. Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination. J Adolesc Health. 2008;43:S52–60.
Gillison ML, Alemany L, Snijders PJ, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine. 2012;30:F34–54.
Hafkamp HC, Speel EJ, Haesevoets A, et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5–8. Int J Cancer. 2003;107:394–400.
Hafkamp HC, Mooren JJ, Claessen SM, et al. P21 Cip1/WAF1 expression is strongly associated with HPV-positive tonsillar carcinoma and a favorable prognosis. Mod Pathol. 2009;22:686–98.
Harrison LBS, Roy B, Waun Ki Hong, editors. Head and neck cancer: a multidisciplinary approach. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2009.
Hoffmann M, Tribius S, Quabius ES, et al. HPV DNA, E6*I-mRNA expression and p16INK4A immunohistochemistry in head and neck cancer – how valid is p16INK4A as surrogate marker? Cancer Lett. 2012;323:88–96.
Hui AB, Lin A, Xu W, et al. Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma. Clin Cancer Res. 2013;19:2154–62.
IARC. IARC monographs on the evaluation of carcinogenic risks to humans human papillomaviruses. Lyon: IARC; 2007.
Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26.
Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature. 1996;380:79–82.
Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14:467–75.
Kuhne C, Banks L. E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box. J Biol Chem. 1998;273:34302–9.
Lajer CB, Nielsen FC, Friis-Hansen L, et al. Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study. Br J Cancer. 2011;104:830–40.
Lajer CB, Garnaes E, Friis-Hansen L, et al. The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer. 2012;106:1526–34.
Li C, Johnson DE. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest. Cell Cycle. 2013;12:923–34.
McLemore MS, Haigentz Jr M, Smith RV, et al. Head and neck squamous cell carcinomas in HIV-positive patients: a preliminary investigation of viral associations. Head Neck Pathol. 2010;4:97–105.
Munger K, Basile JR, Duensing S, et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene. 2001;20:7888–98.
Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–27.
Nasman A, Romanitan M, Nordfors C, et al. Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS One. 2012;7:e38711.
Nedergaard BS, Ladekarl M, Thomsen HF, et al. Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer. Br J Cancer. 2007;97:1135–8.
Nichols AC, Palma DA, Dhaliwal SS, et al. The epidemic of human papillomavirus and oropharyngeal cancer in a Canadian population. Curr Oncol. 2013;20:212–19.
O’Rorke MA, Ellison MV, Murray LJ, et al. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol. 2012;48:1191–201.
Perez-Ordonez B, Beauchemin M, Jordan RC. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol. 2006;59:445–53.
Psyrri A, Sasaki C, Vassilakopoulou M, et al. Future directions in research, treatment and prevention of HPV-related squamous cell carcinoma of the head and neck. Head Neck Pathol. 2012;6:S121–8.
Ramdas L, Giri U, Ashorn CL, et al. miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck. 2009;31:642–54.
Ribeiro KB, Levi JE, Pawlita M, et al. Low human papillomavirus prevalence in head and neck cancer: results from two large case–control studies in high-incidence regions. Int J Epidemiol. 2011;40:489–502.
Rieckmann T, Tribius S, Grob TJ, et al. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother Oncol. 2013;107:242–6.
Salazar CR, Smith RV, Garg MK, et al. Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment. Head Neck Pathol. 2014;8:77–87.
Shin MK, Pitot HC, Lambert PF. Pocket proteins suppress head and neck cancer. Cancer Res. 2006;72:1280–9.
Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer. 2010;116:2166–73.
Strati K, Pitot HC, Lambert PF. Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci U S A. 2006;103:14152–7.
Syrjanen S. The role of human papillomavirus infection in head and neck cancers. Ann Oncol. 2010;21:vii243–5.
Syrjanen KJ, Pyrhonen S, Syrjanen SM, et al. Immunohistochemical demonstration of human papilloma virus (HPV) antigens in oral squamous cell lesions. Br J Oral Surg. 1983;21:147–53.
Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 2007;26:373–400.
Thomas GR, Nadiminti H, Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol. 2005;86:347–63.
Thommes P, Kubota Y, Takisawa H, et al. The RLF-M component of the replication licensing system forms complexes containing all six MCM/P1 polypeptides. EMBO J. 1997;16:3312–19.
Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–10.
Weaver DA, Crawford EL, Warner KA, et al. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer. 2005;4:18.
Westra WH. The changing face of head and neck cancer in the 21st century: the impact of HPV on the epidemiology and pathology of oral cancer. Head Neck Pathol. 2009;3:78–81.
Xie X, Piao L, Cavey GS, et al. Phosphorylation of Nanog is essential to regulate Bmi1 and promote tumorigenesis. Oncogene. 2014;33:2040–52.
Yie SM, Yang H, Ye SR, et al. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol. 2007;128:1002–9.
Zhao M, Rosenbaum E, Carvalho AL, et al. Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer. Int J Cancer. 2005;117:605–10.
zur Hausen H. Papillomavirus infections – a major cause of human cancers. Biochim Biophys Acta. 1996;1288:F55–78.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media Dordrecht
About this entry
Cite this entry
Anandharaj, A., Ekshyyan, O., Moore-Medlin, T., Mehta, V., Nathan, CA.O. (2015). Human Papillomavirus (HPV) Biomarkers in Head and Neck: Squamous Cell Carcinoma (HNSCC). In: Preedy, V., Patel, V. (eds) Biomarkers in Cancer. Biomarkers in Disease: Methods, Discoveries and Applications. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7681-4_31
Download citation
DOI: https://doi.org/10.1007/978-94-007-7681-4_31
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-7680-7
Online ISBN: 978-94-007-7681-4
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences